Article Details
Retrieved on: 2025-02-07 21:49:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses biopharma focusing on the growth of GLP-1 receptor agonists like semaglutide and tirzepatide, highlighting the supply chain shifts prompted by legislative acts like the Biosecure Act. Leading entities including Catalent and Novo Nordisk are mentioned in relation to drug manufacturing advancements and geopolitical influences.
Article found on: www.contractpharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here